Monitor for the company's progress toward the $5M+ Qualified Public Equity Offering by the July 17, 2026 deadline. Failure to raise equity will trigger automatic resignation of lender-appointed directors, likely leading to further distress. The combination of debt financing, board control by lender, and massive share authorization suggests high risk of substantial dilution or potential restructuring.
Price Chart
Executive Summary
BioRestorative Therapies entered into a $1M revolving credit facility with Bowery Group LLC, bearing 12% interest and maturing in one year. Concurrently, three lender-designated directors replaced three existing board members, giving the lender substantial board control. The debt and board changes signal deep financial distress, especially following a recent 20x authorized share increase and a going-concern qualification in the 2025 10-K.
Key Financial Metrics
Key Facts
- Revolving credit facility up to $1,000,000 from Bowery Group LLC at 12% per annum interest, maturing on the first anniversary of closing.
- Default interest rate of 16% per annum.
- Three prior directors (Francisco Silva, Nickolay Kukekov, Patrick F. Williams) resigned effective June 11, 2026.
- Three new directors (Mika Grasso, Katharyn Field, Jatinder Dhaliwal) appointed June 12, 2026, as designees of the lender, giving the lender three of five board seats.
- Loan proceeds to be used for general corporate purposes, including expenses for a Qualified Public Equity Offering of at least $5M.
- Loan agreement requires the company to use reasonable best efforts to consummate a $5M+ equity offering and a total of $10M+ in additional financing within 120 days; failure triggers automatic resignation of lender's board nominees.
- Cross-filing context: 14 days prior, shareholders approved a 20x increase in authorized common shares (75M to 1.5B), creating massive dilution overhang.
Financial Impact
The $1M loan represents ~10% of the $10M market cap and adds interest expense of $120,000/year. The loan is unsecured and pari passu with other unsecured debt. The required $5M+ equity offering will likely cause significant dilution given the authorized share count expansion.
Risk Factors
- Failure to complete a Qualified Public Equity Offering by July 17, 2026 could trigger default or loss of lender-appointed directors, increasing financial instability.
- Massive authorized share increase (1.5B shares) creates severe dilution risk for existing common shareholders, especially if equity is issued at low prices.
- Going-concern qualification in 2025 10-K indicates high risk of bankruptcy or restructuring if equity financing is not obtained.
- Lender board control could lead to actions prioritizing debt repayment over shareholder value.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001021771-26-000091 |
| Exhibit: ex10_2.htm | 0001021771-26-000091 |
| Document: brtx-20260612.htm | 0001021771-26-000091 |
| Document: 0001021771-26-000091-index-headers.html | 0001021771-26-000091 |
| Document: 0001021771-26-000091-index.html | 0001021771-26-000091 |
| Document: 0001021771-26-000091.txt | 0001021771-26-000091 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 8-K | $1.75 | awaiting T+20 | — | $1.62 (−7.43%) |
Sep 11, 2026 6w ago | 8-K | $2.67 $1.91 | ▲ +28.46% | ▲ +30.33% | $1.62 (+39.33%) |
Sep 2, 2026 7w ago | Press Release | $0.1437 $2.14 | ▲ +1389.21% | ▲ +1389.67% | $1.62 (+1027.35%) |
Aug 25, 2026 8w ago | 8-K | $0.2169 $2.51 | ▼ −1057.22% | ▼ −1057.07% | $1.62 (−646.89%) |
Jun 12, 2026 19w ago | 8-K | $0.3910 $0.3400 | ▲ +13.04% | ▲ +13.04% | $1.62 (−314.32%) |
May 29, 2026 21w ago | 8-K | $0.4064 $0.3760 | ▲ +7.48% | ▲ +6.18% | $1.62 (−298.62%) |
May 1, 2026 25w ago | 8-K | $0.2420 $0.4064 | ▲ +67.93% | ▲ +62.29% | $1.62 (+569.42%) |
Apr 7, 2026 28w ago | Press Release | $0.2507 $0.2420 | ▼ −3.47% | ▼ −13.25% | $1.62 (+546.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers